NanoViricides is trading at $1.43 (-5.40%) as biotechnology-sector weakness weighs on shares.
- NanoViricides is declining despite September 23 news that enrollment began in the Phase II NV-387 Mpox trial in the Democratic Republic of Congo.
- The XBI is down 2.04%, alongside broader market losses.
- Treasury yields near 5.14% are pressuring growth-oriented and speculative biotech stocks as inflation concerns intensify.